礼进生物医药科技

Lijin Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation cancer immunotherapies. The company leverages its proprietary xLinkAb platform to create conditionally activated antibodies that aim to enhance therapeutic efficacy while minimizing systemic toxicity. Its lead candidate, a CD40 agonistic antibody, is currently being evaluated in clinical trials for various solid tumors, often in combination with checkpoint inhibitors. Lijin Biotech maintains a robust pipeline of multispecific antibodies targeting key immune checkpoints and costimulatory pathways to address unmet needs in oncology.